The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the curr...The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the current evidence rests on only one randomized controlled trial. SYMPLICITY HTN-3 is a pivotal study started for regulatory purposes in the United States with the goal to evaluate the efficacy and safety of RDN in treatment of resistant hypertension.展开更多
ZTE Corporation （ZTE or the Group） announced on August 19, 2010 that the Group operating revenue increased by 10.89% year-on-year to USD4.524 billion, Revenue contribution from the European and US markets amounted t...ZTE Corporation （ZTE or the Group） announced on August 19, 2010 that the Group operating revenue increased by 10.89% year-on-year to USD4.524 billion, Revenue contribution from the European and US markets amounted to 18% of total revenue for the first time. The year-on-year revenue contribution from these two markets increased bv 45%展开更多
ZTE Corporation (ZTE or the Group) (H share stock code: 0763.HK/A share stock code: 000063.SZ), a leading global provider of telecommunications equipment and network solutions, announced its 3Q
On August 20,2009,ZTE Corporation (ZTE or the Group) announced its Interim results for the day ended June 30,2009.Based on ASBEs and HKAS,ZTE recorded a revenue of
文摘The SYMPLICITY HTN-1 and HTN-2 studies showed that renal denervation （RDN） is feasible as a novel treatment for resistant hypertension. Despite great enthusiasm toward this new treatment modality, until now the current evidence rests on only one randomized controlled trial. SYMPLICITY HTN-3 is a pivotal study started for regulatory purposes in the United States with the goal to evaluate the efficacy and safety of RDN in treatment of resistant hypertension.
文摘ZTE Corporation （ZTE or the Group） announced on August 19, 2010 that the Group operating revenue increased by 10.89% year-on-year to USD4.524 billion, Revenue contribution from the European and US markets amounted to 18% of total revenue for the first time. The year-on-year revenue contribution from these two markets increased bv 45%
文摘ZTE Corporation (ZTE or the Group) (H share stock code: 0763.HK/A share stock code: 000063.SZ), a leading global provider of telecommunications equipment and network solutions, announced its 3Q
文摘On August 20,2009,ZTE Corporation (ZTE or the Group) announced its Interim results for the day ended June 30,2009.Based on ASBEs and HKAS,ZTE recorded a revenue of
